Product Description
Mechanisms of Action: JNK Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Myrexis
Company Location: NEW YORK NY 10020
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Alzheimer Disease
Phase 2: Prostate Cancer|Dermatitis, Atopic|Multiple Sclerosis, Relapsing-Remitting|Melanoma|Skin Cancer
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2014-004483-38 | P2 |
Completed |
Multiple Sclerosis, Relapsing-Remitting |
2018-04-20 |
|
TMP001_MS | P2 |
Completed |
Multiple Sclerosis, Relapsing-Remitting |
2018-04-01 |
|
FLIP0112 | P1 |
Completed |
Healthy Volunteers |
2014-09-01 |
|
2011-002571-42 | P2 |
Completed |
Dermatitis, Atopic |
2012-04-19 |